EPISODE · Jun 4, 2019 · 1H 23M
1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH
This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO. POLO: doi.org/10.1056/NEJMoa1903387 TITAN: doi.org/10.1056/NEJMoa1903307 Back us on Patreon! www.patreon.com/plenarysession
What this episode covers
This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO. POLO: doi.org/10.1056/NEJMoa1903387 TITAN: doi.org/10.1056/NEJMoa1903307 Back us on Patreon! www.patreon.com/plenarysession
NOW PLAYING
1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.